Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.42 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717004 | 0.92 | GCK (0.38) | GCKDGAT1KDM4E | |
| SCHEMBL722328 | 0.88 | GCK (0.36) | GCKDGAT1SOAT2SOAT1DGAT2 | |
| SCHEMBL718710 | 0.84 | KDM4E (0.34) | GCKDGAT1KDM4E | |
| SCHEMBL719057 | 0.83 | DGAT1 (0.42) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL721152 | 0.79 | DGAT1 (0.38) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL717092 | 0.78 | NPC1 (0.37) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL719083 | 0.78 | GCK (0.42) | GCKHCAR3DGAT1SOAT2SOAT1 | |
| SCHEMBL719278 | 0.78 | GCK (0.31) | GCKDGAT1 | |
| SCHEMBL718396 | 0.76 | DGAT1 (0.37) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL718528 | 0.74 | MAOB (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCK 132/4885HCAR3 2764/4885DGAT1 869/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCK 132/4885HCAR3 2764/4885DGAT1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.